Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Anti-Tnf Containing Regimens May Be Associated With Increased Risk of Clostridioides Difficile Infection in Patients With Underlying Inflammatory Bowel Disease Publisher Pubmed



Gholammostafaei FS1 ; Yadegar A2 ; Aghdaei HA1 ; Azimirad M2 ; Daryani NE3 ; Zali MR4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Gastroenterology and Hepatology, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Current Research in Translational Medicine Published:2020


Abstract

Background: Patients with inflammatory bowel disease (IBD) are at greater risk for Clostridioides difficile infection (CDI). There remain controversial issues about the association of infliximab therapy in IBD patients and CDI. Objective: The present work aimed to investigate the potential association between infliximab therapy and the risk of CDI in a group of Iranian patients with IBD. Patients and methods: A total of 140 IBD patients were enrolled, their fresh stool specimens were obtained and used for C. difficile detection. The presence of toxin-encoding genes of C. difficile isolates were examined by PCR. Demographic data, frequency of defecation, antibiotic usage, and IBD therapy were recorded. Results: About half of the IBD patients had a history of antibiotic usage, mostly metronidazole (11.4 %) alone, and metronidazole + ciprofloxacin (16.4 %) as drug combination. C. difficile was isolated from 17.1 % (24/140) of the IBD patients, and more than 90 % of the isolates were found to be toxigenic having genotypes of tcdA+/tcdB+ (18/22, 81.8 %), tcdA+/tcdB− (3/22, 13.6 %) and tcdA−/tcdB+ (1/22, 4.5 %). Interestingly, we only found a significant relationship between the emergence of CDI and the use of infliximab in combinations with other drugs (P = 0.023). Conclusions: In conclusion, there was a considerable incidence of CDI in Iranian patients with IBD. Our study also demonstrated that anti-TNF containing regimens in combinations with other immunosuppressive medications potentially may influence susceptibility to CDI in a group of patients with underlying IBD. Furthermore, our findings recommend avoiding the prolonged use of infliximab along with other corticosteroids or immunomodulators. Further validation studies are needed to better understand the mechanisms that regulate TNF-mediated pathways in CDI pathogenesis among IBD patients. © 2020 Elsevier Masson SAS
Related Docs
1. Clinical and Pathological Features of Ulcerative Colitis in Patients With and Without Clostridium Difficile Infection; an Observational Study, Middle East Journal of Digestive Diseases (2019)
2. Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in Patients With Inflammatory Bowel Disease; Case Series, Govaresh (2017)
3. The Role of Bacteria in the Inflammatory Bowel Disease Development: A Narrative Review, APMIS (2018)
4. Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection in Patients With Concurrent Ulcerative Colitis, Acta Microbiologica et Immunologica Hungarica (2021)
Experts (# of related papers)
View all Related Experts
Najmeh Aletaha (1)
Seyyed Farshad Allameh (1)